Cenix BioScience GmbH
Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery
Published in Immunotherapy Weekly, August 6th, 2008
Cenix will apply its well-established expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells. The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2008-08-06)
More Articles from Immunotherapy Weekly
- University Hospital Heidelberg
Male kidneys for men only? - University of Montreal
Identification of protein able to stimulate production of T-cells - Actinic Keratosis
Data on actinic keratosis described by researchers at University of Regensburg - Angiogenesis
Research from Stanford University provides new data about angiogenesis - Antibody Engineering
Intravenous Gammaglobulin (IVIG) plus Rituximab Improves Chances for Successful Transplantation in High Immunologic-Risk Patients - B-Cell Lymphoma
New B-cell lymphoma study findings have been reported by researchers at Monash University - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
